Top

Current Allergy and Asthma Reports

Published in:

Open Access 18-04-2024 | Dupilumab | Review

Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis

Authors: Hyun J. Yim, Tiffany Jean, Peck Y. Ong

Published in: Current Allergy and Asthma Reports | Issue 5/2024

Abstract

Purpose of Review

Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had long-term adverse effects. Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and newer systemic treatments for AD.

Recent Findings

Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious. High dose cyclosporine and dupilumab were more effective than methotrexate and azathioprine in improving clinical signs of AD. High-dose upadacitinib was shown in another meta-analysis to be most effective in the measured outcomes but had the highest frequency of adverse events.

Summary

Targeted biologic treatments are increasingly favored over traditional immunosuppressive treatments of AD. Treatment can be individualized based on potency, adverse side effects, mechanism of action, and administration preference. Ongoing research continues to expand treatment options for AD.

Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126:417.e2–428.e2.CrossRef

Stander S. Atopic dermatitis. N Engl J Med. 2021;384:1136–43.CrossRefPubMed

Patrick GJ, Archer NK, Miller LS. Which way do we go? Complex interactions in atopic dermatitis pathogenesis. J Invest Dermatol. 2021;141:274–84.CrossRefPubMed

Chong AC, Visitsunthorn K, Ong PY. Genetic/environmental contributions and immune dysregulation in children with atopic dermatitis. J Asthma Allergy. 2022;15:1681–700.CrossRefPubMedPubMedCentral

Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.CrossRefPubMedPubMedCentral

Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–57. https://doi.org/10.1016/j.jaci.2017.01.009.CrossRefPubMed

Albrecht J. The power of topical steroids. JAMA Dermatol. 2022;158:727–9.CrossRefPubMed

Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116–32.CrossRefPubMedPubMedCentral

Davallow Ghajar L, Wood Heickman LK, Conaway M, Rogol AD. Low risk of adrenal insufficiency after use of low- to moderate-potency topical corticosteroids for children with atopic dermatitis. Clin Pediatr (Phila). 2019;58:406–12.CrossRefPubMed

10.

• Axon E, Chalmers JR, Santer M, et al. Safety of topical corticosteroids in atopic eczema: an umbrella review. BMJ Open. 2021;11:e046476. A recent review confirming TCS are well tolerated and effective.

11.

Strowd LC, Feldman SR. Overcoming poor adherence is a major hurdle to managing atopic dermatitis. Br J Dermatol. 2020;182:836–7.CrossRefPubMed

12.

Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211:174–87.CrossRefPubMed

13.

Pena J, Zameza PA, Pixley JN, et al. A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis. J Allergy Clin Immunol Pract. 2023;11:1347–59.CrossRefPubMed

14.

•• AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274–312. https://doi.org/10.1016/j.anai.2023.11.009. The most recent guidelines for atopic dermatitis.

15.

Asgari MM, Tsai AL, Avalos L, et al. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol. 2020;156:1066–73.CrossRefPubMed

16.

Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83:375–81.CrossRefPubMed

17.

• Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7:13–25. A comprehensive study confirming no increased risk of cancer with topical calcineurin inhibitors.

18.

Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306–15. https://doi.org/10.1111/pai.12331.CrossRefPubMedPubMedCentral

19.

Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178:768–75.CrossRefPubMedPubMedCentral

20.

Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953–1040.CrossRefPubMed

21.

Mancuso JB, Lee SS, Paller AS, Ohya Y, Eichenfield LF. Management of severe atopic dermatitis in pediatric patients. J Allergy Clin Immunol Pract. 2021;9(4):1462–71. https://doi.org/10.1016/j.jaip.2021.02.017.CrossRefPubMed

22.

Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema—a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606–19.CrossRefPubMed

23.

Anderson K, Putterman E, Rogers RS, Patel D, Treat JR, Castelo-Soccio L. Treatment of severe pediatric atopic dermatitis with methotrexate: a retrospective review. Pediatr Dermatol. 2019;36:298–302.CrossRefPubMed

24.

Taieb Y, Baum S, Ben AD, Barzilai A, Greenberger S. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. J Dermatolog Treat. 2019;30:240–4.CrossRefPubMed

25.

Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet (London, England). 2006;367:839–46. PubMed PMID:16530578; eng.CrossRefPubMed

26.

Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat. 2009;20:141–5.CrossRefPubMed

27.

Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68:29–35.CrossRefPubMed

28.

Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: Experience in 14 patients. Br J Dermatol. 2007;157:127–32.CrossRefPubMed

29.

Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28:689–94.CrossRefPubMed

30.

Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat. 2020;31(8):810–4. https://doi.org/10.1080/09546634.2019.1642996.CrossRefPubMed

31.

•• Beck LA, Thac ID, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9. Pioneering study in dupilumab.

32.

•• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. https://doi.org/10.1016/S0140-6736(17)31191-1. Long-term dupilumab study with TCS.

33.

Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:44–56.CrossRefPubMed

34.

Paller AS, Siegfried EC, Thac ID, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial [published correction appears in J Am Acad Dermatol;84:230]. J Am Acad Dermatol. 2020;83:1282–93.CrossRefPubMed

35.

Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet. 2022;400:908–19.CrossRefPubMed

36.

Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderateto-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–96.CrossRefPubMed

37.

Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387:2317–30.CrossRefPubMed

38.

Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315:469–79.CrossRefPubMed

39.

Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–63. https://doi.org/10.1111/bjd.19573.CrossRefPubMedPubMedCentral

40.

Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, Pink AE, Chiricozzi A, Barbarot S, Mark T, Tindberg AM, Weidinger S. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022;23(4):547–59. https://doi.org/10.1007/s40257-022-00702-2. Epub 2022 Jul 20. PMID: 35857179; PMCID: PMC9334431.CrossRefPubMedPubMedCentral

41.

Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–91. https://doi.org/10.1056/NEJMoa2206714.CrossRefPubMed

42.

Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740–8. https://doi.org/10.1093/bjd/ljad022.CrossRefPubMed

43.

Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2021 Jun 19;397(10292):2336] [published correction appears in Lancet. 2021 Aug 28;398(10302):746]. Lancet. 2021;397(10290):2169–81. https://doi.org/10.1016/S0140-6736(21)00589-4.CrossRefPubMed

44.

Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol. 2022;149(3):977–987.e14. https://doi.org/10.1016/j.jaci.2021.07.036.CrossRefPubMed

45.

Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–73.CrossRefPubMed

46.

Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66.CrossRefPubMed

47.

Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37(10):2056–66. https://doi.org/10.1111/jdv.19280.

48.

Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66. https://doi.org/10.1016/S0140-6736(20)30732-7.CrossRefPubMed

49.

Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187:338–52.CrossRefPubMed

50.

Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23–32. https://doi.org/10.1093/bjd/ljad096.CrossRefPubMed

51.

• Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659–67. https://doi.org/10.1001/jamadermatol.2020.0796. Systemic review and network meta-analysis of 39 trials with 20 older and newer medications for AD.CrossRefPubMed

52.

• Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523–32. https://doi.org/10.1001/jamadermatol.2022.0455. Updated systemic review and network of 60 trials comparing medications for AD.CrossRefPubMedPubMedCentral

53.

• Chu AWL, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470–92. https://doi.org/10.1016/j.jaci.2023.08.029. Systematic review and network meta-analysis of 149 trials to analyze and compare the benefits and harms of AD systemic treatments.CrossRefPubMed

54.

Ertus C, Scailteux LM, Lescoat A, Berthe P, Auffret V, Dupuy A, Oger E, Droitcourt C. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis. Br J Dermatol. 2023;189(4):368–80. https://doi.org/10.1093/bjd/ljad229.CrossRefPubMed

55.

Chen TL, Lee LL, Huang HK, Chen LY, Loh CH, Chi CC. Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with janus kinase inhibitors: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(11):1254–61. https://doi.org/10.1001/jamadermatol.2022.3516.CrossRefPubMedPubMedCentral

56.

Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693–707. https://doi.org/10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Nov;22(6):905. PMID: 34406619; PMCID: PMC8370859.CrossRefPubMedPubMedCentral

57.

Licata G, Tancredi V, Pezzolo E, Pertusi G, Tolino E, Arisi M, Gambardella A. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023. https://doi.org/10.1111/jdv.19108. Epub ahead of print. PMID: 37017620.CrossRefPubMed

58.

Merola JF, Butler DC, Mark T, Schneider S, Kim Y, Abuabara K. Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: a secondary analysis. JAMA Dermatol. 2023;159(10):1119–23. https://doi.org/10.1001/jamadermatol.2023.2626.CrossRefPubMedPubMedCentral

Title: Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis
Authors: Hyun J. Yim
Tiffany Jean
Peck Y. Ong
Publication date: 18-04-2024
Publisher: Springer US
Keywords: Dupilumab
Atopic Dermatitis
Conjunctivitis
Azathioprine
Azathioprine
Methotrexate
Methotrexate
Published in: Current Allergy and Asthma Reports / Issue 5/2024
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-024-01145-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2024

Environmental Interventions for Preventing Atopic Diseases

Recent Insights into the Environmental Determinants of Childhood Asthma

Fungal Sensitization and Human Allergic Disease

Minimally Invasive Approaches to Diagnose and Monitor Eosinophilic GI Diseases

Pregnancy and the Autoimmune Patient